MedTrace Logo

MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

NCT05776017 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 465

Last updated 2023-04-26

No results posted yet for this study

Summary

Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali

Conditions

  • Malaria,Falciparum

Interventions

BIOLOGICAL

MSP3-CRM-Vac4All/ Alhydrogel®

30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant

BIOLOGICAL

Anti-Rabies Vaccine

Control vaccine

Sponsors & Collaborators

  • Malaria Research and Training Center, Bamako, Mali

    collaborator OTHER

  • Vac4All

    lead INDUSTRY

Principal Investigators

  • Manamadou Thera, MD · MRTC, University of Sciences Techniques and Technologies of Bamako, Mali Locations:

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-27
Primary Completion
2023-12-31
Completion
2024-08-31

Countries

  • Mali

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05776017 on ClinicalTrials.gov